Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Healthy Participants 5Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Solid Tumor, Adult 2Healthy Volunteers 2Breast Neoplasms 2cMET-dysregulated Advanced Solid Tumors 1TP53 Y220C Mutation 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Pain 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Healthy Adult Participants 1Healthy 1Drug-drug Interaction,SHR3680 1Colorectal Neoplasms 1Chronic Cough 1Carcinoma, Squamous Cell 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Advanced Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 11Injections 10tislelizumab 7Nivolumab 4Irinotecan 4Cetuximab 4cediranib 3Paclitaxel 3PM 01183 3Leucovorin 3Gemcitabine 3Fluorouracil 3Cisplatin 3toripalimab 2spartalizumab 2serabelisib 2olaparib 2glumetinib 2camrelizumab 2apatinib 2adagrasib 2Therapeutics 2Pemetrexed 2Oxaliplatin 2Midazolam 2Drug Therapy 2Docetaxel 2Digoxin 2Cyclophosphamide 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumor × Rosuvastatin Calcium × Clear all
NCT04887194 2024-05-08

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Mirati Therapeutics Inc.

Phase 1 Completed
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡